桃红四物汤（THSWD）是一种传统中草药，在临床上广泛用于单独或与其他药物联合治疗乳腺癌。THSWD 的特异性靶向分子及其相关药物分子机制仍不清楚。本研究旨在阐明 THSWD 治疗乳腺癌的分子机制。使用吖啶橙/溴化乙锭 (AO/EB) 染色、 Transwell 实验、流式细胞术、免疫荧光实验和乳腺癌小鼠模型。我们的研究结果表明，THSWD 会诱导乳腺癌细胞坏死和/或凋亡，同时显着抑制细胞迁移。 THSWD 抗癌活性的靶蛋白包括 EGFR、RAS 等。 THSWD 治疗乳腺癌与 EGFR/ERK1/2 信号通路相关。我们的研究结果为 THSWD 在乳腺癌治疗中的主要作用机制提供了初步见解，表明其作为补充疗法的潜力值得进一步研究。版权所有 © 2024。由 Elsevier B.V. 出版

Tao Hong Si Wu Decoction (THSWD), a traditional Chinese herbal medicine, is widely utilized in clinical settings, either alone or in combination with other medications, for the treatment of breast cancer.The specific targeting molecule(s) of THSWD and its associated molecular mechanisms remain unclear. This research aims to elucidate the underlying molecular mechanisms of THSWD in the treatment of breast cancer.The pharmacological properties of THSWD were investigated in breast cancer cells and tumor tissues using a range of methods including Acridine Orange/Ethidium Bromide (AO/EB) staining, Transwell assay, flow cytometry, immunofluorescence assay, and breast cancer mice models.Our findings demonstrate that THSWD induces necrosis and/or apoptosis in breast cancer cells, while significantly inhibiting cell migration. Target proteins of THSWD in anticancer activity include EGFR, RAS, and others. THSWD treatment for breast cancer is associated with the EGFR/ERK1/2 signaling pathway.Our findings offer initial insights into the primary mechanism of action of THSWD in breast cancer treatment, indicating its potential as a complementary therapy deserving further investigation.Copyright © 2024. Published by Elsevier B.V.